Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity

Triple Negative Breast Cancer (TNBC), the most aggressive subtype of breast cancer, is characterized by the absence of hormone receptors usually targeted by hormone therapies like Tamoxifen. Because therapy success and survival rates for TNBC lag far behind other breast cancer subtypes, there is sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Fultang, Norman, Illendula, Abhinav, Chen, Brian, Wu, Chun, Jonnalagadda, Subash, Baird, Nathan, Klase, Zachary, Peethambaran, Bela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544296/
https://www.ncbi.nlm.nih.gov/pubmed/31150511
http://dx.doi.org/10.1371/journal.pone.0217789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544296/
https://www.ncbi.nlm.nih.gov/pubmed/31150511
http://dx.doi.org/10.1371/journal.pone.0217789

Ejemplares similares